In re Medtronic, Inc. Shareholder Litigation.

CourtCourt of Appeals of Minnesota
DecidedJanuary 25, 2016
DocketA15-858
StatusUnpublished

This text of In re Medtronic, Inc. Shareholder Litigation. (In re Medtronic, Inc. Shareholder Litigation.) is published on Counsel Stack Legal Research, covering Court of Appeals of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Medtronic, Inc. Shareholder Litigation., (Mich. Ct. App. 2016).

Opinion

This opinion will be unpublished and may not be cited except as provided by Minn. Stat. § 480A.08, subd. 3 (2014).

STATE OF MINNESOTA IN COURT OF APPEALS A15-0858

In re Medtronic, Inc. Shareholder Litigation.

Filed January 25, 2016 Affirmed in part, reversed in part, and remanded Reyes, Judge

Hennepin County District Court File No. 27CV1411452

Vernon J. Vander Weide, Gregg M. Fishbein, Richard A. Lockridge, Lockridge, Grindal, Nauen, P.L.L.P., Minneapolis, Minnesota; and

Mark C. Gardy, James S. Notis, Jennifer Sarnelli, Gardy & Notis, LLP, New York, New York; and

Emily Komlossy, Ross Appel, Komlossy Law, P.A., Hollywood, Florida (for appellant)

James K. Langdon, Michelle S. Grant, James K. Nichols, Dorsey & Whitney, LLP, Minneapolis, Minnesota (for respondents)

Considered and decided by Peterson, Presiding Judge; Halbrooks, Judge; and Reyes,

Judge.

UNPUBLISHED OPINION

REYES, Judge

Appellant challenges the district court’s dismissal of his class-action suit against

respondents arising out of respondent Medtronic, Inc.’s acquisition of an Irish

corporation through an inversion, asserting that the inversion caused him to incur

significant capital-gains taxes and diluted his corporate ownership. Appellant argues that the district court erred by (1) dismissing ten of his claims as derivative and for failing to

comply with Minn. R. Civ. P. 23.09 and (2) dismissing two of his claims for failure to

state a claim under Minn. R. Civ. P. 12.02(e). We affirm in part, reverse in part, and

remand.

FACTS

Appellant has pleaded the following facts relevant to the appeal. On March 25,

2014, José É. Alméida, the chief executive officer of Covidien (an Irish public limited

company), contacted Omár Ishrak, the chief executive officer of respondent Medtronic,

Inc. (at the time, a Minnesota public company), to set up an in-person meeting to discuss

a potential merger between the two companies. Following that meeting, the parties

discussed potential merger options, including Medtronic acquiring Covidien through an

“inversion.”

In an inversion transaction, Medtronic would no longer be a Minnesota-based

company but would be incorporated in Ireland (New Medtronic). As a result,

Medtronic’s future foreign earnings would not be subject to U.S. federal income taxes.

In order to recover some of the future lost federal-income-tax revenue, the Internal

Revenue Service (IRS) imposes an excise tax (or capital-gains tax) on any shares held in

taxable accounts by a company’s shareholders.1 According to Medtronic’s Form S-4,

neither Medtronic nor Covidien would be subject to this excise tax (“None of Covidien or

1 See I.R.C. Code § 7874 (2014) (addressing tax on inversion gain of expatriated entities); see also I.R.C. § 4985 (2014) (providing that a 15% excise tax is imposed on the value of stock compensation in 2014). Congress imposed this tax to discourage inversion transactions.

2 New Medtronic are expected to be subject to U.S. federal income tax as a result of the

merger or the scheme.”). And, in order to avoid violating IRS regulations, all Medtronic

shareholders would incur a significant dilution in their shares that would not have been

required in a non-inversion transaction.

Respondent Medtronic board of directors,2 spoke with Covidien via teleconference

in May 2014 to further discuss the potential inversion, Medtronic’s foreign-cash reserves,

Covidien’s financial value, Covidien’s potential tax-free access to their overseas cash,

and the impact of the merger. Notably, as part of the inversion proposal, Medtronic

would provide its senior executives and the Individual Respondents a gross-up payment

or “Excise Tax Reimbursement” of more than $60 million to compensate them for the

excise tax they would incur as shareholders due to the inversion. No other Medtronic

shareholders would receive this Excise Tax Reimbursement. Finally, Medtronic agreed

to pay Covidien $850 million if the Medtronic shareholders did not ratify the inversion

transaction.

At the end of May 2014, Medtronic and Covidien negotiated the purchase price of

Covidien, and on June 2, 2014, the Medtronic CEO and the Covidien CEO “reached a

nonbinding oral understanding” to purchase Covidien at $92.50 per share. The next day,

the Medtronic Board and Covidien approved the transaction to purchase Covidien at

$92.50 per share. On June 15, 2014, Medtronic announced the inversion, by which

2 The Medtronic board of directors is composed of individual respondents Ishrak, Anderson, Donnelly, Dzau, Jackson, Leavitt, Lenehan, O’Leary, Powell, Pozen, and Reddy (Individual Respondents or the Medtronic Board).

3 Medtronic would acquire Covidien. On that same day, Perella Weinberg Partners LP, an

independent advisory and asset-management firm, provided an opinion to the Medtronic

Board, and they opined that the consideration Medtronic would pay was fair to Medtronic

and to its shareholders. Accordingly, the Medtronic Board approved the inversion.

On July 2, 2014, appellant Lewis Merenstein filed a class-action suit against

respondents. Appellant challenges “the decision to structure the acquisition as an

inversion[, which] caused harm, both as to the [excise] taxes he is being forced to pay and

as to that part of the dilution [in his corporate ownership] attributable to the need to

comply with the IRS’s anti-inversion regulations.” On September 26, 2014, the district

court granted an order consolidating appellant’s action with another shareholder’s later-

filed action.

The complaint alleges the following counts. Appellant alleges harm to him and

Medtronic’s shareholders by the Individual Respondents for self-dealing (count I), breach

of fiduciary duties (count II), and breaches of the standard of conduct for both officers

and directors pursuant to Minn. Stat. §§ 302A.251, .361 (2014) (counts III and IV).

Count V seeks equitable relief pursuant to Minn. Stat. § 302A.467 for each of these

breaches. Counts VI and VIII-X allege harm based on violations of Minn. Stat.

§ 302A.255 (2014) (count VI), §§ 302A.165, .251, .255, .521 (2014) (count VIII),

§§ 302A.011, subd. 10, .551, .557, .559 (2014) (count IX), and § 302A.165 (count X).

Count VII alleges harm based on Minn. Stat. § 302A.521. Counts XI and XII allege

harm based on violations of Minn. Stat. §§ 80A.68, .76 (2014) (count XI), and

§§ 80A.69, .76 (2014) (count XII).

4 Respondents moved for dismissal pursuant to Minn. R. Civ. P. 23.09 and Minn. R.

Civ. P. 12.02(e), asserting that all the counts are derivative. The district court granted

respondents’ motion to dismiss on March 20, 2015, concluding that counts I-X are

derivative claims and that appellant failed to follow the procedures mandated by

rule 23.09.3 The district court further concluded that, although counts XI and XII were

direct claims, appellant failed to state a claim for relief pursuant to rule 12.02(e). This

appeal follows.

DECISION

Appellant challenges the district court’s conclusions that counts I-X are derivative

and therefore subject to rule 23.09 and that counts XI-XII fail to state a claim under rule

12.02(e). Appellant also argues that the district court mischaracterized and contradicted

certain allegations and failed to credit certain other factual allegations. After carefully

reviewing each count, we conclude that the district court erred in determining that counts

Free access — add to your briefcase to read the full text and ask questions with AI

Related

TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Mesko v. Cabletron System, Inc.
311 F.3d 11 (First Circuit, 2002)
Blohm v. Kelly
765 N.W.2d 147 (Court of Appeals of Minnesota, 2009)
Minneapolis Employees Retirement Fund v. Allison-Williams Co.
519 N.W.2d 176 (Supreme Court of Minnesota, 1994)
Professional Management Associates, Inc. v. Coss
598 N.W.2d 406 (Court of Appeals of Minnesota, 1999)
Bahr v. CAPELLA UNIVERSITY
788 N.W.2d 76 (Supreme Court of Minnesota, 2010)
Tooley v. Donaldson, Lufkin, & Jenrette, Inc.
845 A.2d 1031 (Supreme Court of Delaware, 2004)
Northwest Racquet Swim & Health Clubs, Inc. v. Deloitte & Touche
535 N.W.2d 612 (Supreme Court of Minnesota, 1995)
Martens v. Minnesota Mining & Manufacturing Co.
616 N.W.2d 732 (Supreme Court of Minnesota, 2000)
Wessin v. Archives Corp.
592 N.W.2d 460 (Supreme Court of Minnesota, 1999)
Northern States Power Co. v. Franklin
122 N.W.2d 26 (Supreme Court of Minnesota, 1963)
Stocke v. Berryman
632 N.W.2d 242 (Court of Appeals of Minnesota, 2001)
Laura L. Walsh v. U.S. Bank, N.A.
851 N.W.2d 598 (Supreme Court of Minnesota, 2014)
Parnes v. Gateway 2000, Inc.
122 F.3d 539 (Eighth Circuit, 1997)
Seitz v. Michel
181 N.W. 106 (Supreme Court of Minnesota, 1921)
Merry v. Prestige Capital Markets, Ltd.
944 F. Supp. 2d 702 (D. Minnesota, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
In re Medtronic, Inc. Shareholder Litigation., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-medtronic-inc-shareholder-litigation-minnctapp-2016.